Therapy Areas: Oncology
Ascentage Pharma to Present Phase 1 Interim Results of Two Clinical Programmes at 2018 ASCO Annual Meeting
23 May 2018 - - Rockville, Maryland- and Hong Kong-based clinical-stage biopharmaceutical company Ascentage Pharma will present interim results from two clinical programmes at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 1-5, 2018, the company said.
APG-1252 was designed to reduce the target platelet toxicity seen with dual inhibitors Bcl-2/Bcl-xL, while maintaining strong antitumor activity.
Preliminary results showed that APG-1252 was well-tolerated with no hematologic toxicity reported. There was one confirmed partial response in a metastatic small cell lung cancer (SCLC) patient. Dose escalation continues in SCLC and other solid tumors.
APG-1387, an IAP inhibitor, was well-tolerated with manageable adverse events. Preliminary responses indicated positive host immune responses, suggesting synergy with immunotherapy agents.
Studies are continuing with APG-1387 in combination with immunotherapy agents in patients with advanced solid tumors or hematologic malignancies.
Ascentage Pharma is dedicated to developing apoptosis-targeted small molecule therapies for cancers, hepatitis B, and age-related diseases.
The company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
It has a pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.
Login
Username:

Password: